Login / Signup

Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin.

Anne-Kathrine RyltoftAli Al-ZuhairySøren Hein SindrupHenning AndersenLars K Markvardsen
Published in: Acta neurologica Scandinavica (2020)
In SCIG treated CIDP patients QoL is reduced and correlates to gait performance and disability.
Keyphrases
  • newly diagnosed
  • end stage renal disease
  • ejection fraction
  • prognostic factors
  • oxidative stress
  • peritoneal dialysis